Circulating retinol binding protein 4 levels in nonalcoholic fatty liver disease: a systematic review and meta-analysis

Zhou, Zhongwei; Chen, Hongmei; Ju, Huixiang; Sun, Mingzhong

doi:10.1186/s12944-017-0566-7

Cited by 26 publications

(12 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This presumably reflects the resilience and regenerative capacity of the liver and is also in line with the fact that NAFLD or early cirrhosis is often asymptomatic and clinically difficult to detect. Circulating RBP4 levels are among the changes that have been controversially discussed in the literature, with some studies finding higher levels in NAFLD (Terra et al , ) and some reporting unchanged levels (Zhou et al , ). This parallels our plasma proteome data, in which RBP4 was clearly significant in cirrhosis but not in the NAFLD sub‐groups.…”

Section: Discussionmentioning

confidence: 99%

Plasma proteome profiling discovers novel proteins associated with non‐alcoholic fatty liver disease

Niu

Geyer

Albrechtsen

et al. 2019

Molecular Systems Biology

184

171

View full text Add to dashboard Cite

Non‐alcoholic fatty liver disease ( NAFLD ) affects 25% of the population and can progress to cirrhosis with limited treatment options. As the liver secretes most of the blood plasma proteins, liver disease may affect the plasma proteome. Plasma proteome profiling of 48 patients with and without cirrhosis or NAFLD revealed six statistically significantly changing proteins ( ALDOB , APOM , LGALS 3 BP , PIGR , VTN , and AFM ), two of which are already linked to liver disease. Polymeric immunoglobulin receptor ( PIGR ) was significantly elevated in both cohorts by 170% in NAFLD and 298% in cirrhosis and was further validated in mouse models. Furthermore, a global correlation map of clinical and proteomic data strongly associated DPP 4, ANPEP , TGFBI , PIGR , and APOE with NAFLD and cirrhosis. The prominent diabetic drug target DPP 4 is an aminopeptidase like ANPEP , ENPEP , and LAP 3, all of which are up‐regulated in the human or mouse data. Furthermore, ANPEP and TGFBI have potential roles in extracellular matrix remodeling in fibrosis. Thus, plasma proteome profiling can identify potential biomarkers and drug targets in liver disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Plasma proteome profiling discovers novel proteins associated with non‐alcoholic fatty liver disease

Niu

Geyer

Albrechtsen

et al. 2019

Molecular Systems Biology

184

171

View full text Add to dashboard Cite

show abstract

“…Contrary to the positive associations reported for the human studies considered above, a meta-analysis carried out to determine whether NAFLD or NASH patients have altered blood RBP4 levels was unable to identify such a relationship (Zhou et al, 2017). The metaanalysis involved published data from 12 studies comprising 4247 participants including 2271 NAFLD patients and 1976 controls.…”

Section: A Vitamin a Vitamin A-related Proteins And Liver Diseasementioning

confidence: 96%

Vitamin A signaling and homeostasis in obesity, diabetes, and metabolic disorders

Blaner

2019

Pharmacology & Therapeutics

189

149

View full text Add to dashboard Cite

Much evidence has accumulated in the literature over the last fifteen years that indicates vitamin A has a role in metabolic disease prevention and causation. This literature proposes that vitamin A can affect obesity development and the development of obesity-related diseases including insulin resistance, type 2 diabetes, hepatic steatosis and steatohepatitis, and cardiovascular disease. Retinoic acid, the transcriptionally active form of vitamin A, accounts for many of the reported associations. However, a number of proteins involved in vitamin A metabolism, including retinolbinding protein 4 (RBP4) and aldehyde dehydrogenase 1A1 (ALDH1A1, alternatively known as retinaldehyde dehydrogenase 1 or RALDH1), have also been identified as being associated with metabolic disease. Some of the reported effects of these vitamin A-related proteins are proposed to be independent of their roles in assuring normal retinoic acid homeostasis. This review will consider both human observational data as well as published data from molecular studies undertaken in rodent models and in cells in culture. The primary focus of the review will be on the effects that vitamin A per se and proteins involved in vitamin A metabolism have on adipocytes, adipose tissue biology, and adipose-related disease, as well as on early stage liver disease, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

show abstract

“…Plasma retinol-binding protein 4 (RBP4) is a 21-kDa transporter of all- trans -retinol and belongs to the lipocalin family [56, 57]. RBP4 circulates in plasma as a moderately tight 1:1 M complex with vitamin A. RBP4 is secreted mainly by hepatocytes and also by adipose tissue [58].…”

Section: Lipocalin Family In Humansmentioning

confidence: 99%

Update on the human and mouse lipocalin (LCN) gene family, including evidence the mouse Mup cluster is result of an “evolutionary bloom”

et al. 2019

View full text Add to dashboard Cite

Lipocalins (LCNs) are members of a family of evolutionarily conserved genes present in all kingdoms of life. There are 19 LCN -like genes in the human genome, and 45 Lcn -like genes in the mouse genome, which include 22 major urinary protein ( Mup ) genes. The Mup genes, plus 29 of 30 Mup-ps pseudogenes, are all located together on chromosome (Chr) 4; evidence points to an “evolutionary bloom” that resulted in this Mup cluster in mouse, syntenic to the human Chr 9q32 locus at which a single MUPP pseudogene is located. LCNs play important roles in physiological processes by binding and transporting small hydrophobic molecules —such as steroid hormones, odorants, retinoids, and lipids—in plasma and other body fluids. LCNs are extensively used in clinical practice as biochemical markers. LCN-like proteins (18–40 kDa) have the characteristic eight β-strands creating a barrel structure that houses the binding-site; LCNs are synthesized in the liver as well as various secretory tissues. In rodents, MUPs are involved in communication of information in urine-derived scent marks, serving as signatures of individual identity, or as kairomones (to elicit fear behavior). MUPs also participate in regulation of glucose and lipid metabolism via a mechanism not well understood. Although much has been learned about LCNs and MUPs in recent years, more research is necessary to allow better understanding of their physiological functions, as well as their involvement in clinical disorders.

show abstract

Circulating retinol binding protein 4 levels in nonalcoholic fatty liver disease: a systematic review and meta-analysis

Cited by 26 publications

References 42 publications

Plasma proteome profiling discovers novel proteins associated with non‐alcoholic fatty liver disease

Plasma proteome profiling discovers novel proteins associated with non‐alcoholic fatty liver disease

Vitamin A signaling and homeostasis in obesity, diabetes, and metabolic disorders

Update on the human and mouse lipocalin (LCN) gene family, including evidence the mouse Mup cluster is result of an “evolutionary bloom”

Contact Info

Product

Resources

About